The CEO's sale is a textbook cashless exercise pattern (option exercise + immediate sale to cover taxes and realize gains) following a 364% stock appreciation from the $21.58 strike. At 0.12% of market cap, this cluster is too small to signal fundamental concern. The Q1 earnings beat and $200M rusfertide milestone are the dominant catalysts. Monitor for any secondary offerings or insider sales exceeding 0.5% of market cap in the next 30 days.
PTGX drugs
PTGX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $99.36entry
- T+1 · 6mo ago +4.17%α +3.93% · $103.50
- T+5 · 6mo ago +6.23%α +4.77% · $105.55
- T+20 · 5mo ago −1.99%α −2.02% · $97.38
- T+60 · 3mo ago +36.68%α +31.85% · $135.81
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protagonist Therapeutics CEO Dinesh Patel sold $7.5M worth of stock on May 12, 2026, following a $600K sale by Director Bryan Giraudo on May 8, creating a two-insider sell cluster totaling $8.11M. The sales occurred just 9 days after a massive Q1 earnings beat (revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus) driven by milestone payments from ICOTYDE FDA approval and the rusfertide opt-out. While the earnings beat is clearly positive, the CEO's large open-market sale immediately after exercising options at $21.58/share (realizing ~$7.5M profit) is a routine cashless exercise pattern, the stock is up ~364% from the option strike, and the sale represents only ~0.12% of the $6.7B market cap, falling below the 0.5% materiality threshold.
Key Financial Metrics
Key Facts
- CEO Dinesh Patel sold 75,000 shares at $100.12 for $7.51M on May 12, 2026, after exercising options at $21.58/share
- Director Bryan Giraudo sold 6,000 shares at $100.00 for $600K on May 8, 2026
- Total cluster value: $8.11M, representing ~0.12% of PTGX's $6.7B market cap
- Sales occurred 9 days after Q1 2026 earnings beat: revenue $56.4M vs $16.3M consensus, EPS $0.05 vs -$0.65 consensus
- CEO's option exercises were non-cash (A/F) or at $21.58 strike, the $7.5M sale is a standard cashless exercise pattern, not a bearish signal
- Prior 30-day insider activity showed 4 sells totaling $19.2M, consistent with routine post-vesting diversification
Financial Impact
Total insider sales of $8.11M represent ~0.12% of $6.7B market cap, well below the 0.5% materiality threshold for significant insider selling
Risk Factors
- CEO sold 100% of the exercised shares, no retention signals confidence beyond the option exercise itself
- Stock is up significantly post-earnings; additional insider sales could emerge as lockups expire
- The $200M rusfertide payment is a one-time event, future quarters will need to show recurring revenue from ICOTYDE sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTGX-1778803638393 |
Track record
11 reports on PTGX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Viewing Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers